Skip to main content
Wiley Open Access Collection logoLink to Wiley Open Access Collection
. 2021 Jan 25;106(4):593. doi: 10.1111/ejh.13575

Blinatumomab vs historic standard‐of‐care treatment for minimal residual disease in adults with B‐cell precursor acute lymphoblastic leukaemia

PMCID: PMC8173652  PMID: 33751649

In Gökbuget et al, 1 the affiliation for Dr Giovanni Martinelli was published incorrectly.

The affiliation should have read:

9Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.

We apologise for this error.

. Blinatumomab vs historic standard‐of‐care treatment for minimal residual disease in adults with B‐cell precursor acute lymphoblastic leukaemia. Eur J Haematol. 2021;106:593–593. 10.1111/ejh.13575

REFERENCE

  • 1. Gökbuget N, Dombret H, Giebel S, et al. Blinatumomab vs historic standard‐of‐care treatment for minimal residual disease in adults with B‐cell precursor acute lymphoblastic leukaemia. Eur J Haematol. 2020;104:299‐309. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from European Journal of Haematology are provided here courtesy of Wiley

RESOURCES